Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07619417 · ClinicalTrials.gov registry record · NA

Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms

A NA study, sponsored by Ohio State University Comprehensive Cancer Center.

Not yet
Registry status
NA
Development phase
12
Enrollment target

NCT07619417 is a NA study that has not yet begun recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07619417, a NA study, has not yet begun recruiting, sponsored by Ohio State University Comprehensive Cancer Center.

NOT YET RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target

Study Summary

This clinical trial tests the safety and feasibility of endoscopic ultrasound-guided pulsed electric field ablation for the treatment of pancreatic neoplasms. Pancreatic cancer is a fatal disease that is difficult to diagnose at an early stage. The approach for pancreatic neoplasm treatment has changed and the recognition of minimally invasive treatments is growing. One such minimally invasive treatment, known as endoscopic ultrasound-guided pulsed electric field ablation, offers an alternative to surgery for managing certain precancerous or high-risk pancreatic cysts. The Aliya Pulsed Electric Field system uses brief, strong bursts of electricity, delivered through a thin needle, to destroy targeted tissue, such as tumors, without using heat. These electric pulses damage only the cells inside the treatment zone, leaving the healthy tissues and important nearby structures unharmed. This makes the treatment safer and less likely to cause harm to sensitive areas around the tumor. Endoscopic ultrasound-guided pulsed electric field ablation may be safe and feasible for the treatment of pancreatic neoplasms.

Interventions

  • OTHER Electronic Health Record Review
  • OTHER Clinical Intervention or Procedure
  • PROCEDURE Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2026-08-01
Est. Completion 2027-12-31
Phase NA

What the Registry Record Tells You About NCT07619417

The ClinicalTrials.gov registry entry for NCT07619417 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Electronic Health Record Review is the first listed.

NCT07619417 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07619417 about?

NCT07619417 is a clinical study titled "Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms". This clinical trial tests the safety and feasibility of endoscopic ultrasound-guided pulsed electric field ablation for the treatment of pancreatic neoplasms. Pancreatic cancer is a fatal disease that is difficult to diagnose at an early stage. The approach for pancreatic neoplasm treatment has chan...

What is the current status of trial NCT07619417?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2026-08-01. Estimated completion is 2027-12-31.

What interventions are being tested in trial NCT07619417?

The interventions under investigation include: Electronic Health Record Review (OTHER), Clinical Intervention or Procedure (OTHER), Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas (PROCEDURE).

Who is sponsoring clinical trial NCT07619417?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.